Trifluoperazine 2HClCAS# 440-17-5 |
- GDC-0068 (RG7440)
Catalog No.:BCC1271
CAS No.:1001264-89-6
- MK-2206 dihydrochloride
Catalog No.:BCC1274
CAS No.:1032350-13-2
- AZD5363
Catalog No.:BCC1073
CAS No.:1143532-39-1
- A-443654
Catalog No.:BCC1321
CAS No.:552325-16-3
- AKT inhibitor VIII
Catalog No.:BCC1334
CAS No.:612847-09-3
Quality Control & MSDS
3D structure
Package In Stock
Number of papers citing our products
| Cas No. | 440-17-5 | SDF | Download SDF |
| PubChem ID | 66064 | Appearance | Powder |
| Formula | C21H26Cl2F3N3S | M.Wt | 480.42 |
| Type of Compound | N/A | Storage | Desiccate at -20°C |
| Solubility | DMSO : 50 mg/mL (104.08 mM; Need ultrasonic) H2O : 50 mg/mL (104.08 mM; Need ultrasonic) | ||
| Chemical Name | 10-[3-(4-methylpiperazin-1-yl)propyl]-2-(trifluoromethyl)phenothiazine;dihydrochloride | ||
| SMILES | [H+].[H+].[Cl-].[Cl-].CN1CCN(CCCN2c3ccccc3Sc4ccc(cc24)C(F)(F)F)CC1 | ||
| Standard InChIKey | BXDAOUXDMHXPDI-UHFFFAOYSA-N | ||
| Standard InChI | InChI=1S/C21H24F3N3S.2ClH/c1-25-11-13-26(14-12-25)9-4-10-27-17-5-2-3-6-19(17)28-20-8-7-16(15-18(20)27)21(22,23)24;;/h2-3,5-8,15H,4,9-14H2,1H3;2*1H | ||
| General tips | For obtaining a higher solubility , please warm the tube at 37 ℃ and shake it in the ultrasonic bath for a while.Stock solution can be stored below -20℃ for several months. We recommend that you prepare and use the solution on the same day. However, if the test schedule requires, the stock solutions can be prepared in advance, and the stock solution must be sealed and stored below -20℃. In general, the stock solution can be kept for several months. Before use, we recommend that you leave the vial at room temperature for at least an hour before opening it. |
||
| About Packaging | 1. The packaging of the product may be reversed during transportation, cause the high purity compounds to adhere to the neck or cap of the vial.Take the vail out of its packaging and shake gently until the compounds fall to the bottom of the vial. 2. For liquid products, please centrifuge at 500xg to gather the liquid to the bottom of the vial. 3. Try to avoid loss or contamination during the experiment. |
||
| Shipping Condition | Packaging according to customer requirements(5mg, 10mg, 20mg and more). Ship via FedEx, DHL, UPS, EMS or other couriers with RT, or blue ice upon request. | ||
Trifluoperazine 2HCl Dilution Calculator
Trifluoperazine 2HCl Molarity Calculator
| 1 mg | 5 mg | 10 mg | 20 mg | 25 mg | |
| 1 mM | 2.0815 mL | 10.4076 mL | 20.8151 mL | 41.6302 mL | 52.0378 mL |
| 5 mM | 0.4163 mL | 2.0815 mL | 4.163 mL | 8.326 mL | 10.4076 mL |
| 10 mM | 0.2082 mL | 1.0408 mL | 2.0815 mL | 4.163 mL | 5.2038 mL |
| 50 mM | 0.0416 mL | 0.2082 mL | 0.4163 mL | 0.8326 mL | 1.0408 mL |
| 100 mM | 0.0208 mL | 0.1041 mL | 0.2082 mL | 0.4163 mL | 0.5204 mL |
| * Note: If you are in the process of experiment, it's necessary to make the dilution ratios of the samples. The dilution data above is only for reference. Normally, it's can get a better solubility within lower of Concentrations. | |||||
Calcutta University
University of Minnesota
University of Maryland School of Medicine
University of Illinois at Chicago
The Ohio State University
University of Zurich
Harvard University
Colorado State University
Auburn University
Yale University
Worcester Polytechnic Institute
Washington State University
Stanford University
University of Leipzig
Universidade da Beira Interior
The Institute of Cancer Research
Heidelberg University
University of Amsterdam
University of Auckland
TsingHua University
The University of Michigan
Miami University
DRURY University
Jilin University
Fudan University
Wuhan University
Sun Yat-sen University
Universite de Paris
Deemed University
Auckland University
The University of Tokyo
Korea University
Trifluoperazine is a dopamine D2 receptor inhibitor with IC50 of 1.1 nM.
- Isoscabertopin
Catalog No.:BCN4634
CAS No.:439923-16-7
- Gnetifolin M
Catalog No.:BCN3394
CAS No.:439900-84-2
- NPY 5RA972
Catalog No.:BCC7747
CAS No.:439861-56-0
- BMS-509744
Catalog No.:BCC1424
CAS No.:439575-02-7
- ITK inhibitor
Catalog No.:BCC1662
CAS No.:439574-61-5
- GW 627368
Catalog No.:BCC7961
CAS No.:439288-66-1
- Lasmiditan
Catalog No.:BCC4077
CAS No.:439239-90-4
- Bay 60-7550
Catalog No.:BCC1405
CAS No.:439083-90-6
- Afatinib
Catalog No.:BCC3656
CAS No.:439081-18-2
- O-2093
Catalog No.:BCC7070
CAS No.:439080-01-0
- Gentianine
Catalog No.:BCN5492
CAS No.:439-89-4
- 2-Amino-3-methylbenzoic acid
Catalog No.:BCC8528
CAS No.:4389-45-1
- K 579
Catalog No.:BCC2364
CAS No.:440100-64-1
- WAY 200070
Catalog No.:BCC7669
CAS No.:440122-66-7
- 3-Phenyl-2-propen-1-ol
Catalog No.:BCN5493
CAS No.:4407-36-7
- Benzoin oxime
Catalog No.:BCC8858
CAS No.:441-38-3
- Eribulin mesylate
Catalog No.:BCC5173
CAS No.:441045-17-6
- 2-(Cyanomethyl)benzimidazole
Catalog No.:BCC8483
CAS No.:4414-88-4
- 6-Acetylacteoside
Catalog No.:BCC8109
CAS No.:441769-43-3
- Macitentan
Catalog No.:BCC1142
CAS No.:441798-33-0
- Harmine
Catalog No.:BCN5494
CAS No.:442-51-3
- Clemizole
Catalog No.:BCC1485
CAS No.:442-52-4
- Aspertine C
Catalog No.:BCN2153
CAS No.:442155-62-6
- CK-636
Catalog No.:BCC5107
CAS No.:442632-72-6
Reprint of: A chemical screen identifies trifluoperazine as an inhibitor of glioblastoma growth.[Pubmed:29580626]
Biochem Biophys Res Commun. 2018 May 5;499(2):136-142.
Glioblastoma (GBM) is regarded as the most common malignant brain tumor but treatment options are limited. Thus, there is an unmet clinical need for compounds and corresponding targets that could inhibit GBM growth. We screened a library of 80 dopaminergic ligands with the aim of identifying compounds capable of inhibiting GBM cell line proliferation and survival. Out of 45 active compounds, 8 were further validated. We found that the dopamine receptor D2 antagonist Trifluoperazine 2HCl inhibits growth and proliferation of GBM cells in a dose dependent manner. Trifluoperazine's inhibition of GBM cells is cell line dependent and correlates with variations in dopamine receptor expression profile. We conclude that components of the dopamine receptor signaling pathways are potential targets for pharmacological interventions of GBM growth.
A chemical screen identifies trifluoperazine as an inhibitor of glioblastoma growth.[Pubmed:29066348]
Biochem Biophys Res Commun. 2017 Dec 16;494(3-4):477-483.
Glioblastoma (GBM) is regarded as the most common malignant brain tumor but treatment options are limited. Thus, there is an unmet clinical need for compounds and corresponding targets that could inhibit GBM growth. We screened a library of 80 dopaminergic ligands with the aim of identifying compounds capable of inhibiting GBM cell line proliferation and survival. Out of 45 active compounds, 8 were further validated. We found that the dopamine receptor D2 antagonist Trifluoperazine 2HCl inhibits growth and proliferation of GBM cells in a dose dependent manner. Trifluoperazine's inhibition of GBM cells is cell line dependent and correlates with variations in dopamine receptor expression profile. We conclude that components of the dopamine receptor signaling pathways are potential targets for pharmacological interventions of GBM growth.
Photosafety screening of phenothiazine derivatives with combined use of photochemical and cassette-dosing pharmacokinetic data.[Pubmed:24241722]
Toxicol Sci. 2014 Feb;137(2):469-77.
This study aimed to establish an efficient photosafety screening system, employing in vitro photochemical and cassette-dosing pharmacokinetic (PK) studies. Eight phenothiazine (PTZ) derivatives were selected as model chemicals, and photochemical characterization and cassette-dosing PK study were carried out. In vivo photosafety testing on oral PTZs (100 mg/kg) was also assessed in rats. All the tested PTZs exhibited potent UVA/B absorption with molar extinction coefficients of ca. 3400-4400 M(-1)cm(-1). Under exposure to simulated sunlight (2.0 mW/cm(2)), all PTZs, especially fluphenazine 2HCl (FP) and Trifluoperazine 2HCl (TF), tended to generate reactive oxygen species (ROS). Casset-dosing PK studies demonstrated high dermal deposition of FP and TF in rats, and from these findings, taken together with the potent photochemical reactivity, both FP and TF were deduced to be highly phototoxic. In contrast, the phototoxic potential of chlorpromazine HCl (CP) seemed to be low because of moderate ROS generation and limited dermal distribution. Predicted phototoxic risk for PTZs from photochemical and PK data appeared basically to agree with the observed phototoxicity in rats; however, oral CP (100 mg/kg) caused severe phototoxic responses in rats. Metabolites of CP have been recognized to be phototoxic, which might explain in part this false prediction. These findings might also suggest the necessity of complementary testing on drug metabolites for more reliable photosafety evaluation. The combined use of photochemical and PK data might be efficacious for simple and fast prediction of the phototoxic potential of new drug candidates.
